INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. — XBIT

NEW YORK, NY / ACCESSWIRE / October 19, 2017 / Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. (“XBiotech”) (NASDAQ: XBIT) concerning possible violations of federal securities laws.

On April 20, 2017, XBiotech announced that the European Medicines Agency (“EMA”) had rendered a negative trend vote after meeting with the Company to discuss its marketing authorization application (“MAA”) for XBiotech’s candidate antibody for the treatment of colorectal cancer. Then, on May 18, 2017, XBiotech announced it had received a negative opinion for its MAA. Then, on June 9, 2017, XBiotech announced it had discontinued a Phase 3 study for the treatment after the findings “were not sufficient to meet efficacy or the threshold for continuation.” To obtain additional information, go to:

http://www.zlkdocs.com/XBIT-Info-Request-Form-5678

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street- 24th Floor
New York, NY10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 478312